Rain Therapeutics, Roche to collaborate on clinical trial of milademetan combination with anti-PD-L1 immunotherapy for solid tumors

Humana and Evolent expand partnership to enhance oncology care

Humana Inc. and Evolent Health Inc. announced an expansion of their strategic medical oncology partnership to modernize and streamline prior authorization processes to include radiation and surgical oncology services.

November 15, 2024

Vol.50 No.43

Clinical Roundup

CAP publishes guideline for PD-L1 testing for lung cancer

The College of American Pathologists in collaboration with the International Association for the Study of Lung Cancer, Pulmonary Pathology Society, Association for Molecular Pathology, and the LUNGevity Foundation have developed evidence-based recommendations for the testing of immunotherapy biomarkers, including programmed cell death ligand-1 and tumor mutation burden in patients with non-small cell lung carcinoma.

April 19, 2024

Vol.50 No.16

Drugs & Targets

Shasqi, Johnson & Johnson expand existing research collaboration

Shasqi, Inc. and Johnson & Johnson Enterprise Innovation Inc. have expanded their ongoing research collaboration.

October 13, 2023

Vol.49 No.38

Drugs & Targets

Pierre Fabre Laboratories, Vernalis partner to advance cancer research

Pierre Fabre Laboratories and Vernalis, a fully owned subsidiary of HitGen Inc., established a long-term partnership to identify pre-clinical candidates against oncology targets.

September 29, 2023

Vol.49 No.36

Regulatory News

ODAC gives thumbs-up to GSK plan to build on MSK rectal cancer study of dostarlimab that produced 100% response

Can a single drug replace a long-established curative, albeit brutal, regimen of chemotherapy, radiation, and surgery?

February 10, 2023

Vol.49 No.06

By Jacquelyn Cobb and Paul Goldberg

Guest Editorial

ODAC clears a path for dostarlimab, a drug that may “beat the reaper” in locally advanced rectal cancer

Cancer specialists like me, whether they are medical, surgical, or radiation oncologists spend our lives treating life threatening disease. We generally have a serious and professional demeanor reflective of the world that we choose to inhabit and the circumstances facing our patients that entrust us with their care.

February 10, 2023

Vol.49 No.06

By Richard M. Goldberg